Lung Function
Nasal IL-26 levels heightened in smokers with COPD, reflect disease symptoms
Long-term smokers with and without mild to moderate COPD had raised nasal IL-26 levels, which were correlated to symptom/health impairment assessments, according to data published in Journal of Allergy and Clinical Immunology.
CFTR modulator use during pregnancy preserves maternal lung function
Percent-predicted FEV1 measured before pregnancy did not fall 1 year after in women with highly effective cystic fibrosis transmembrane conductance regulator modulator exposure during pregnancy, according to data published in CHEST.
Wood dust exposure negatively impacts lung function in carpenters
Between a group of carpenters and an age-, sex- and height-matched group of university employees, carpenters had worse average lung function values, according to results published in BMC Pulmonary Medicine.
Race-neutral lung function equations alter FEV1, FVC in pediatric patients with asthma
SAN DIEGO — Following use of race-neutral lung function equations, African American and Latino pediatric patients with asthma had reductions in FEV1 and FVC while white patients with asthma had increases, according to a presentation here.
Admilparant slows lung function decline in IPF, progressive PF
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.
Individuals with impaired FEV1/FVC trajectories often experience wheeze before middle age
Around 20% to 25% of individuals with rapidly declining FEV1/FVC trajectories experienced wheezing and usual phlegm/bronchitis as adolescents/young adults, according to results published in The Lancet Respiratory Medicine.
Positive topline data reported in phase 3 trial of nerandomilast in progressive PF
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.
Genetic risk score plus lung function questionnaire improves COPD prediction
The ability to predict spirometry-defined COPD was significantly better when a modified lung function questionnaire score was used in combination with a COPD polygenic risk score, according to results published in JAMA.
FDA grants brensocatib priority review for bronchiectasis
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release.
Immunotherapy platform for ALS slows disease progression, extends survival
A new analysis of an overall survival study of an investigational immunotherapy platform to treat ALS found it slowed disease progression and extended survival, according to the manufacturer.